Eip Pharma, LLC

Vertex Pharmaceuticals, Inc.

John Jahangir Alam

Jeffrey Douglas Wilson

Ene Ikpong Ette

Lindsay McNair

Hui-May Chu

Provided herein are co-crystal forms comprising 5-(2,6-dichlorophenyl)-2-(2,4-difluorophenylthio)-6H-pyrimido[1,6-b]pyridazin-6-one (VX-745): and compositions thereof, useful as inhibitors of one or more protein kinases and which exhibit desirable characteristics for the same.

Co-crystals of neflamapimod (VX-745)

Disclosed are oral pharmaceutical compositions of neflamapimod that exhibit suitable exposure for administration in humans and/or that maintain a desirable dissolution profile under standard storage conditions.

Pharmaceutical formulations of neflamapimod

The present invention provides methods and compositions for improving episodic memory and treating dementia.

Compositions and methods for treating dementia

The present invention provides methods for treating a neurological disorder.

Methods for treating neurologic disorders

The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.

Compositions and methods for treating Alzheimer's disease

The present invention provides methods and compositions for promoting recovery of function from neurologic injury, such as ischemic injury caused by acute stroke.

Methods and compositions for recovery from stroke

Compositions and methods for treating alzheimer's disease

The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.

Growing community of inventors

Cambridge, MA, United States of America

John Jahangir Alam